Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. C, 51-54
© 1999 The British Society for Antimicrobial Chemotherapy
Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study
Institut Neuchâtelois de Microbiologie, La Chaux-de-Fonds, Switzerland
The objective of this study was to examine the susceptibility of clinical isolates to levofloxacin, a fluoroquinolone with extended activity against Gram-positive bacteria, and other antibiotics in 12 Swiss clinical microbiology laboratories using the NCCLS disc diffusion technique. Isolates were prospectively collected from intensive care units (ICUs) (59%), oncology wards (7%) and other units with haematology/oncology patients (34%) from June 1995 to March 1996. The levofloxacin breakpoints used were as recommended by the manufacturer. A total of 310 Gram-positive and 580 Gram-negative isolates from the respiratory tract (36%), skin/wounds (12%), blood (16%), urine (17%) and other sources (19%) were tested. The percentage of isolates susceptible to levofloxacin was 100% for Enterococcus spp. (38 strains), Streptococcus agalactiae (13), Streptococcus pneumoniae (65), Acinetobacter spp. (11), Citrobacter diversus (6), Citrobacter freundii (17), Klebsiella oxytoca (39), Morganella morganii (16), Proteus mirabilis (20), Proteus vulgaris (23), Serratia spp. (19), Stenotrophomonas maltophilia (10) and Haemophilus influenzae (41). The percentage of isolates susceptible to levofloxacin for Staphylococcus aureus (95 strains, including 2% MRSA) was 94%, coagulase-negative staphylococci (85) 65%, Enterobacter spp. (75) 99%, Escherichia coli (111) 97%, Klebsiella pneumoniae (45) 98% and Pseudomonas aeruginosa (124) 87%. In conclusion, levofloxacin is a new fluoroquinolone to which the most common clinical isolates in Switzerland are susceptible. The susceptibility of Enterococcusspp. and S. pneumoniae to levofloxacin was particularly remarkable. This compound appears to be a promising therapeutic alternative for the treatment of Gram-positive infections.
* Correspondence address. Institut Neuchâtelois de Cydalise 16, CH-2300 La Chaux-de-Fonds, Switzerland. Tel: +41-32-967-2101; Fax: +41-32-968-2643; E-mail: hans.siegrist{at}fnis.etatne.ch
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. Noreddin, V. L. Haynes, and G. G. Zhanel Pharmacokinetics and Pharmacodynamics of the New Quinolones Journal of Pharmacy Practice, December 1, 2005; 18(6): 432 - 443. [Abstract] [PDF]
|
|
|
|
 |
|
 C. B. Washington, S. Y. E. Hou, C. Campanella, N. Hughes, S. Brown, and B. Berner Pharmacokinetics and Pharmacodynamics of a Novel Extended-Release Ciprofloxacin in Healthy Volunteers J. Clin. Pharmacol., November 1, 2005; 45(11): 1236 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Regoes, C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, and B. R. Levin Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3670 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Ba, H. Feghali, C. Arpin, M.-C. Saux, and C. Quentin Activities of Ciprofloxacin and Moxifloxacin against Stenotrophomonas maltophilia and Emergence of Resistant Mutants in an In Vitro Pharmacokinetic-Pharmacodynamic Model Antimicrob. Agents Chemother., March 1, 2004; 48(3): 946 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Seral, S. Carryn, P. M. Tulkens, and F. Van Bambeke Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus J. Antimicrob. Chemother., May 1, 2003; 51(5): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|